NDAINTRAVENOUSSOLUTION
Approved
Dec 2012
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
4
Data completeness
6/8 — Strong
IMMPHENTIV (phenylephrine hydrochloride) by Hikma is α-1 adrenergic receptor agonist. Approved for nasal congestion, seasonal allergic rhinitis, vasomotor rhinitis. First approved in 2012.
Drug data last refreshed 20h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
IMMPHENTIV is an intravenous solution of phenylephrine hydrochloride, an α-1 adrenergic receptor agonist approved in 2012. It is indicated for nasal congestion, seasonal allergic rhinitis, and vasomotor rhinitis through selective stimulation of peripheral α-1 receptors. The drug operates as a sympathomimetic vasoconstrictor to reduce nasal mucosal edema.
Peak10.4 years to LOE
Product is in peak commercial phase with no Part D spending data available; modest team size expected for niche IV indication.
Mechanism of Action
α-1 adrenergic receptor agonist.
Indications (3)
Worked on IMMPHENTIV at Hikma? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.